← SynDRA
MIRDAMETINIB
SynDRA canonical compound SYN0011671 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP2K1 |
|---|
| Mechanism of action | Protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MEK inhibitor
- Protein kinase inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- MAPK15
- PIM2
- PIM1
- PIK3CG
- PIK3CD
- PIK3CB
- PIK3CA
- PIK3C2G
- PIK3C2B
- PI4KB
- PHKG2
- PHKG1
- PGRMC1
- PFKP
- PDXK
- PDPK1
- PDGFRB
- PDGFRA
- PCYT1A
- PASK
- PAK6
- PAK5
- PAK4
- PAK3
- PAK2
- PAK1
- PAICS
- OXSR1
- PIM3
- PIP4K2A
- PIP4K2B
- PRKACB
- PRKCZ
- PRKCQ
- PRKCI
- PRKCH
- PRKCE
- PRKCD
- PRKCB
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- GOMEKLI
- Gomekli
- PD-0325901
- Pd 03525901
- Pd 901
- PD 0325901
- PD-325901
- PD0325901
- PD325901
- S06-0029
- PD-901
- DTXCID8024024
- CHEBI:88249
- RefChem:818905
- MEK Inhibitor PD0325901
- C16H14F3IN2O4
- Mirdametinib [USAN]
- Mirdametinib (USAN)
- NCGC00189075-01
- MFCD08435926
- UNII-86K0J5AK6M
- Ezmekly
- PD0325901(Mirdametinib)
- 4BM
- Ezmekly (TN)
- Gomekli (TN)
- Mirdametinib (GMP)
- MIRDAMETINIB [INN]
- MIRDAMETINIB [WHO-DD]
- SCHEMBL172904
- GTPL7935
- orb1300996
- PD0325901 (Mirdametinib)
- SCHEMBL29352748
- SCHEMBL29358470
- EX-A102
- BDBM104963
- GLXC-90133
- HMS3648A14
Look up MIRDAMETINIB in the interactive SynDRA portal →